Researchers at the National University of Singapore (NUS) have developed a scalable, non-viral technology that efficiently ...

We show that CL22-mediated transfection of hmoDCs with antigen expressing plasmids enabled the DCs to stimulate autologous T cells in vitro such that they developed antigen-specific CTL activity.

MicroRNA-27a has been shown to stimulate both the wingless-type integration site family, or Wnt signaling, and the bone morphogenetic protein pathways to actively promote bone regeneration, according ...

We hypothesized that MitoT can target immunocompetent cells and play a role in the regulation of T‐cell function, contributing to the dampening of inflammation that is associated with MSC therapy.

Background: It has been suggested that defective handling of apoptotic cells by macrophages plays a key role in the development of systemic lupus erythematosus (SLE). The relative contribution of ...

Get Instant Summarized Text (Gist) Generative AI has been used to design synthetic DNA regulatory sequences that precisely control gene expression in healthy mammalian cells. These AI-generated ...

HCC1428, SKBR3, MCF7, and Jurkat cells were maintained at 37°C with 5% CO 2 RPMI1640 ... cells were treated with C48 at the indicated concentrations 1 day after transfection for a total of 5 days. In ...

As it applies to the development of cell therapies, AstraZeneca’s chief of global operations, Pam Cheng, admits that the company is a “little late to join the party.” But just because AZ has ...

Department of Chemistry, Kangwon National University, Chuncheon 24341, Republic of Korea Multidimensional Genomics Research Center, Kangwon National University, Chuncheon 24341, Republic of Korea ...

† Department of Biochemistry and Biophysics, Texas A&M University, College Station, Texas 77843-2128, United States ‡ Department of Chemistry, Texas A&M University, College Station, Texas 77843-3255, ...

The facility, which was previously used by Novartis to manufacture the gene therapy Zolgensma, was picked up by BMS in early 2023 to bolster viral vector capacity for its commercial cell therapy ...